TITLE

pharmaceuticals & fine chemicals

PUB. DATE
January 2007
SOURCE
Chemical Week;1/3/2007, Vol. 169 Issue 1, p31
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents updates on companies in the industry of pharmaceuticals and fine chemicals. Actavis Group has acquired a manufacturing plant from Grandix Pharmaceuticals. Lonza has agreed to license its glutamine synthetase expression system and GS-CHO protein free system to Roche for the manufacture of therapeutic recombinant proteins and monoclonal antibodies.
ACCESSION #
23771860

 

Related Articles

  • Recent Shifts Among Vitamin Manufacturers Create New World Order of Fierce Competition. Mirasol, Feliza // Chemical Market Reporter;2/28/2005, Vol. 267 Issue 9, p6 

    The article reports on the business activities among vitamin manufacturers. With the 2003 acquisition of Roche AG's vitamins unit by DSM Nutritional Products Inc. and the 2001 acquisition of Takeda Chemical Industries Ltd.'s vitamins operations by BASF AG, as well as other significant shifts in...

  • Roche.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p83 

    Features the Roche Holding Ltd., a pharmaceutical manufacturer. Focus of its international research and development efforts; Total shares at the biotechnology company, Genentech Inc.; Pharmaceutical products that have received approval from the United States Food and Drug Administration.

  • Legal costs batter Roche's profits. Beacham, Will // European Chemical News;3/3/2003, Vol. 78 Issue 2042, p9 

    Reports the financial performance of Swiss pharmaceutical company Roche in 2002. Factors that influenced its financial performance; Overview of its financial results; Expectations for 2003.

  • Global Report.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p10 

    The article offers information related to the pharmaceutical industry such as the end of the deal to supply drugs between Roche and the state-funded hospitals in Greece, and the adoption by the European Commission (EC) of the revised proposals on supplying prescription-only drugs to the public.

  • It's Roche vs Schering-Plough for hepatitis-C market.  // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p10 

    Reports on Roche AG's receipt of U.S. Food and Drug Administration approval for Pegasys, a drug for treatment of hepatitis C. Marketing program; Competition with PEG-Intron from Schering-Plough.

  • Roche's Pharma Pipeline Beginning to Blossom. Jarvis, Lisa // Chemical Market Reporter;9/3/2001, Vol. 260 Issue 9, p12 

    Presents information on potentially important products from Roche's pharmaceutical division as a result of improvements made in the research and development approach. Overview on Roche's hepatitis C treatment Pegasys; Company's cycle cell inhibitor for the treatment of solid tumors; Roche's...

  • Healthy combo.  // Business News New Jersey;10/02/96, Vol. 9 Issue 20, p3 

    Focuses on the business partnership formed between Bayer AG's Consumer Care Division and Roche Holding AG to market a batch of the firms' over-the-counter drugs.

  • Brazil, Roche set drug price.  // Medical Marketing & Media;Oct2001, Vol. 36 Issue 10, p24 

    Reports the agreement of Roche to meet the request of the Brazilian government to reduce the cost of Viracept.

  • Top 5 Bio/Pharma Deals This Year.  // BioWorld Insight;10/25/2010, Vol. 18 Issue 43, p7 

    A table is presented that depicts the top five biotechnology and pharmaceutical company deals of 2010 including Rigel Corp., AstraZeneca PLC, and Roche Holdings AG.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics